Le Lézard
Classified in: Health, Science and technology
Subject: PER

Rebellis Group Adds New Executives


SAN FRANCISCO, July 9, 2020 /PRNewswire/ -- Today Rebellis Group, LLC, announces that April Fleming and Charro Knight-Lilly, both former Gorman Health Group executives, have joined Rebellis Group.

"Deb and I are extremely excited to announce the addition of April and Charro as owners and principal consultants at Rebellis Group. Deb and I have worked with April and Charro for many years, and know that their combined experience will have a meaningful impact on our firm" says Betsy Seals, co-founder of Rebellis Group.

Before founding Rebellis Group, Betsy Seals served as the Chief Consulting Officer, Deb Devereaux as the SVP of Pharmacy Operations, Charro Knight-Lilly as the Chief Sales Officer, and April Fleming as the SVP of Product Development at Gorman Health Group, prior to its acquisition in August of 2017.

Combined, the Rebellis Group ownership team bring decades of operational, product development, compliance, and leadership experience, having served hundreds of clients, including some of the nation's largest and most well-known managed care companies.

Designed for today's healthcare organization, Rebellis Group offers a full spectrum of services to assist in streamlining and optimizing systems and processes, connecting the dots between strategic and operational functions to maximize revenues, increasing agility, and developing fundamental insights for effective management with projects spanning all aspects of the organization, including executive strategy support, vendor evaluation, auditing, and software implementation management.

Rebellis Group is serving clients nationwide with satellite offices in Northern California, Colorado, Missouri, Florida, Arizona, and Georgia. Please visit www.rebellisgroup.com to learn more.

About Charro Knight-Lilly, Principal, Rebellis Group

Charro is an experienced healthcare executive with over 25 years in managed care programs.  Charro is particularly skilled in business strategy and planning, new plan implementation and expansion, Medicare compliance, sales and Marketing, and operations. Charro's deep understanding of health plan operations combined with her extensive regulatory background allows her to support clients in achieving operational and compliance excellence.  

About April Flaming, Principal, Rebellis Group

April is an accomplished executive with almost twenty years' experience in the Medicare Advantage and Part D managed care industry.  Additionally, April has an extensive software development background, having managed the development of multiple SaaS products, including software design, programming, testing, implementation, and client support.  She brings to Rebellis Group an affinity for translating complex regulatory guidance and business needs into technical requirements and operational practices.

SOURCE Rebellis Group


These press releases may also interest you

at 07:45
Sensi.AI, a leader in AI-native, data, and analytics in senior care, today announced the appointment of in-home care leader Bob Roth to its Advisory Board. This partnership is an exciting validation of Sensi.AI's promise to enhance proactive,...

at 07:05
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...



News published on and distributed by: